The estimated Net Worth of V, Llcsv Life Sciences Fund... is at least $505 Tausend dollars as of 30 June 2015. V Fund owns over 391,090 units of Astria Therapeutics Inc stock worth over $505,047 and over the last 9 years V sold CATB stock worth over $0.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
V Fund CATB stock SEC Form 4 insiders trading
V has made over 2 trades of the Astria Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently V bought 391,090 units of CATB stock worth $4,693,080 on 30 June 2015.
The largest trade V's ever made was buying 391,090 units of Astria Therapeutics Inc stock on 30 June 2015 worth over $4,693,080. On average, V trades about 391,090 units every 0 days since 2015. As of 30 June 2015 V still owns at least 59,139 units of Astria Therapeutics Inc stock.
You can see the complete history of V Fund stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Astria Therapeutics Inc
Over the last 9 years, insiders at Astria Therapeutics Inc have traded over $0 worth of Astria Therapeutics Inc stock and bought 3,064,797 units worth $36,777,564 . The most active insiders traders include Jean George, Nicholas Galakatos und Lifesciences Ii, L.P.Clarus.... On average, Astria Therapeutics Inc executives and independent directors trade stock every 0 days with the average trade being worth of $2,617,339. The most recent stock trade was executed by Lifesciences Ii, L.P.Clarus... on 30 June 2015, trading 376,695 units of CATB stock currently worth $4,520,340.
What does Astria Therapeutics Inc's logo look like?
Complete history of V Fund stock trades at Astria Therapeutics Inc
Astria Therapeutics Inc executives and stock owners
Astria Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Jill Milne,
President, Chief Executive Officer, Co-Founder, Director -
Joanne Donovan,
Chief Medical Officer -
Andrew Nichols,
Chief Scientific Officer -
Kenneth Bate,
Independent Chairman of the Board -
Michael Kishbauch,
Independent Director -
Gregg Lapointe,
Independent Director -
Burt Adelman,
Independent Director -
Hugh Cole,
Independent Director -
Joanne Beck,
Independent Director -
Andrew Komjathy,
Chief Commercial Officer -
Benjamin Harshbarger,
Senior Vice President, General Counsel -
Noah Clauser,
Chief Financial Officer -
Andrea Matthews,
IR Contact Officer -
Rick Modi,
Chief Business Officer -
Jean George,
Director -
V, Llcsv Life Sciences Fund...,
-
Ron Laufer,
Director -
Michael Jay Ross,
Director -
Michael Jirousek,
Chief Scientific Officer -
Lifesciences Ii, L.P.Clarus...,
-
Ian C. Sanderson,
Chief Financial Officer -
Ventures, Inc. Med Immune,
10% owner -
Nicholas Galakatos,
Director -
Edward K. Hibben,
Chief Business Officer -
Fred Callori,
Director -
Jonathan Violin,
Director -
Deirdre A. Cunnane,
Chief Legal Officer -
Advisors Llcperceptive Life...,